Viral Hepatitis

You have full text access to this OnlineOpen article

Expression of pituitary tumor–transforming gene 1 (PTTG1)/securin in hepatitis B virus (HBV)-associated liver diseases: Evidence for an HBV X protein–mediated inhibition of PTTG1 ubiquitination and degradation†

  1. Francisca Molina-Jiménez1,2,
  2. Ignacio Benedicto1,2,
  3. Miki Murata3,
  4. Samuel Martín-Vílchez2,4,
  5. Toshihito Seki3,
  6. José Antonio Pintor-Toro5,
  7. María Tortolero6,
  8. Ricardo Moreno-Otero2,4,
  9. Kazuichi Okazaki3,
  10. Kazuhiko Koike7,
  11. José Luchi Barbero8,
  12. Koichi Matsuzaki3,
  13. Pedro L. Majano1,2,‡,
  14. Manuel López-Cabrera1,2,9,‡,§,*

Article first published online: 30 NOV 2009

DOI: 10.1002/hep.23468

Issue

Hepatology

Hepatology

Volume 51, Issue 3, pages 777–787, March 2010

Additional Information

How to Cite

Molina-Jiménez, F., Benedicto, I., Murata, M., Martín-Vílchez, S., Seki, T., Antonio Pintor-Toro, J., Tortolero, M., Moreno-Otero, R., Okazaki, K., Koike, K., Barbero, J. L., Matsuzaki, K., Majano, P. L. and López-Cabrera, M. (2010), Expression of pituitary tumor–transforming gene 1 (PTTG1)/securin in hepatitis B virus (HBV)-associated liver diseases: Evidence for an HBV X protein–mediated inhibition of PTTG1 ubiquitination and degradation. Hepatology, 51: 777–787. doi: 10.1002/hep.23468

Author Information

  1. 1

    Unidad de Biología Molecular, Hospital Universitario de la Princesa, Madrid, Spain

  2. 2

    Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

  3. 3

    Depdatamaticsf Gastroenterology and Hepatogips Kansai Medical University, Osaka, Japan

  4. 4

    Unidad de Hepatología, Hospital Universitario de la Princesa, Madrid, Spain

  5. 5

    Centro Andaluz de Biología Molecular y Medicina Regenerativa, Sevilla, Spain

  6. 6

    Departamento de Microbiología, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain

  7. 7

    Department of Infectious Diseases, Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

  8. 8

    Departamento de Biología Celular y del Desarrollo, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain

  9. 9

    Centro de Biología Molecular Severo Ochoa (CBMSO), CSIC-UAM, Madrid, Spain

  1. ‡

    These authors contributed equally to this work.

  2. §

    fax: (34)-91-3093911

*Unidad de Biología Molecular, Hospital Universitario de La Princesa, C/Diego de León 62, 28006 Madrid, Spain

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 2 MAR 2010
  2. Article first published online: 30 NOV 2009
  3. Accepted manuscript online: 30 NOV 2009 12:00AM EST
  4. Manuscript Accepted: 28 OCT 2009
  5. Manuscript Received: 12 MAR 2009

Funded by

  • CIBERehd (funded by ISCIII)
  • Ministerio de Educación y Ciencia. Grant Number: SAF2007-61201
  • Ministerio de Educación y Ciencia. Grant Numbers: CP03/0020 from ISCIII, SAF2007-60677
  • ISCIII
  • Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa
  • CIBERehd

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (2585K)

References

  • 1
    Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 2006; 25: 3823–3833.
  • 2
    Tang H, Oishi N, Kaneko S, Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci 2006; 97: 977–983.
  • 3
    Su Q, Schroder CH, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. HEPATOLOGY 1998; 27: 1109–1120.
  • 4
    Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH, et al. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007; 132: 1476–1494.
  • 5
    Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 2004; 18: 382–384.
  • 6
    Kalra N, Kumar V. The X protein of hepatitis B virus binds to the F box protein Skp2 and inhibits the ubiquitination and proteasomal degradation of c-Myc. FEBS Lett 2006; 580: 431–436.
  • 7
    Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997; 11: 433–441.
  • 8
    Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999; 285: 418–422.
  • 9
    Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007; 28: 165–186.
  • 10
    Gil-Bernabe AM, Romero F, Limon-Mortes MC, Tortolero M. Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol 2006; 26: 4017–4027.
  • 11
    Limon-Mortes MC, Mora-Santos M, Espina A, Pintor-Toro JA, Lopez-Roman A, et al. UV-induced degradation of securin is mediated by SKP1-CUL1-beta TrCP E3 ubiquitin ligase. J Cell Sci 2008; 121: 1825–1831.
  • 12
    Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49–54.
  • 13
    Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, et al. Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis. HEPATOLOGY 2006; 43: 1267–1275.
  • 14
    Bernal JA, Luna R, Espina A, Lazaro I, Ramos-Morales F, Romero F, et al. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat Genet 2002; 32: 306–311.
  • 15
    Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. HEPATOLOGY 2006; 43: 1042–1052.
  • 16
    Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. HEPATOLOGY 1994; 19: 810–819.
  • 17
    Lee S, Tarn C, Wang WH, Chen S, Hullinger RL, Andrisani OM. Hepatitis B virus X protein differentially regulates cell cycle progression in X-transforming versus nontransforming hepatocyte (AML12) cell lines. J Biol Chem 2002; 277: 8730–8740.
  • 18
    Yun C, Cho H, Kim SJ, Lee JH, Park SY, Chan GK. Mitotic aberration coupled with centrosome amplification is induced by hepatitis B virus X oncoprotein via the Ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res 2004; 2: 159–169.
  • 19
    Benedicto I, Molina-Jimenez F, Bartosch B, Cosset FL, Lavillette D, Prieto J, et al. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 2009; 83: 8012–8020.
  • 20
    Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, et al. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 2000; 19: 403–409.
  • 21
    Koike K, Moriya K, Yotsuyanagi H, Iino S, Kurokawa K. Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts. J Clin Invest 1994; 94: 44–49.
  • 22
    Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci U S A 1995; 92: 11215–11219.
  • 23
    Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78: 12725–12734.
  • 24
    Yun C, Lee JH, Park H, Jin YM, Park S, Park K, et al. Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells. Oncogene 2000; 19: 5163–5172.
  • 25
    Lara-Pezzi E, Majano PL, Gomez-Gonzalo M, Garcia-Monzon C, Moreno-Otero R, Levrero M, et al. The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. HEPATOLOGY 1998; 28: 1013–1021.
  • 26
    Huang J, Kwong J, Sun EC, Liang TJ. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol 1996; 70: 5582–5591.
  • 27
    Traweger A, Fang D, Liu YC, Stelzhammer W, Krizbai IA, Fresser F, et al. The tight junction-specific protein occludin is a functional target of the E3 ubiquitin-protein ligase itch. J Biol Chem 2002; 277: 10201–10208.
  • 28
    Romero F, Gil-Bernabe AM, Saez C, Japon MA, Pintor-Toro JA, Tortolero M. Securin is a target of the UV response pathway in mammalian cells. Mol Cell Biol 2004; 24: 2720–2733.
  • 29
    Feitelson MA, Reis HM, Liu J, Lian Z, Pan J. Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis. Front Biosci 2005; 10: 1558–1572.
  • 30
    Mukherji A, Janbandhu VC, Kumar V. HBx-dependent cell cycle deregulation involves interaction with cyclin E/A-cdk2 complex and destabilization of p27Kip1. Biochem J 2007; 401: 247–256.
  • 31
    Banks L, Pim D, Thomas M. Viruses and the 26S proteasome: hacking into destruction. Trends Biochem Sci 2003; 28: 452–459.
  • 32
    Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438–449.
  • 33
    Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007; 130: 21–24.
  • 34
    Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. HEPATOLOGY 2007; 46: 558–565.
  • 35
    Yu R, Lu W, Chen J, McCabe CJ, Melmed S. Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology 2003; 144: 4991–4998.
  • 36
    Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317–320.
  • 37
    Livezey KW, Negorev D, Simon D. Increased chromosomal alterations and micronuclei formation in human hepatoma HepG2 cells transfected with the hepatitis B virus HBX gene. Mutat Res 2002; 505: 63–74.
  • 38
    Kim S, Park SY, Yong H, Famulski JK, Chae S, Lee JH, et al. HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint. Oncogene 2008; 27: 3457–3464.
View Full Article with Supporting Information (HTML) Get PDF (2585K)